These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23029129)

  • 1. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
    Calvet X; Ruíz MÀ; Dosal A; Moreno L; López M; Figuerola A; Suarez D; Miquel M; Villoria A; Gené E
    PLoS One; 2012; 7(9):e45604. PubMed ID: 23029129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
    Calvet X; Gené E; ÀngelRuíz M; Figuerola A; Villoria A; Cucala M; Mearin F; Delgado S; Calleja JL
    Technol Health Care; 2016; 24(1):111-20. PubMed ID: 26409561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
    Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
    J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
    Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
    Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
    Wilson PD; Hutchings A; Jeans A; Macdougall IC
    J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 9. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P; Dahlerup JF
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.
    Zhang F; Shen A; Ahmed W; Pollock RF
    Adv Ther; 2024 Nov; 41(11):4191-4204. PubMed ID: 39292421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
    Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L
    Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy and safety of intravenous ferric carboxymaltose for the management of iron deficiency anaemia in Malaysia: A single centre cohort study.
    Kamarul HNB
    Med J Malaysia; 2024 Sep; 79(5):517-524. PubMed ID: 39352152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.
    Grimmelt AC; Cohen CD; Fehr T; Serra AL; Wuethrich RP
    Clin Nephrol; 2009 Feb; 71(2):125-9. PubMed ID: 19203504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
    Laass MW; Straub S; Chainey S; Virgin G; Cushway T
    BMC Gastroenterol; 2014 Oct; 14():184. PubMed ID: 25326048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.